Schizophrenia
Conditions
Interventions
Perospirone
Aripiprazole
Sponsors
Department of Neuropsychiatry, Kansai Medical University
Hyogo University of Health Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients (inpatients and outpatients) over 15 years of age, who were diagnosed with schizophrenia (according to the DSM-IV criteria) and were required to have scores PANSS total score 60 or more, and a score 4 or more on at least two of the PANSS-positive items assessing delusions, hallucinatory behavior or conceptual disorganization, were eligible. Patients for whom the total dose of antipsychotics (haloperidol equivalent dose) is lower than 12.0 mg/day at screening.
Exclusion criteria
Exclusion criteria: Patient with coma; under the depressant by barbiturates, received perospirone or aripiprazole within 4 weeks (30 days), participated in a clinical study or post-marketing clinical study within 12 months (180 days), were pregnant or may become pregnant or nursing, history of drug and alcohol abuse, neuroleptic malignant syndrome, water intoxication, known hypersensitivity to study drugs, significant risk of suicide, currently epinephrine administration precluded entry into the study, and patients considered as inadequate by investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Positive and Negative Syndrome Scale Gene polymorphism | — |
Secondary
| Measure | Time frame |
|---|---|
| Drug-Induced Extrapyramidal Symptoms Scale Barnes Akathisia Scale Clinical Global Impression | — |
Countries
Japan
Contacts
Public ContactYoshiteru Takekita
Kansai Medical University Department of Neuropsychiatry
Outcome results
None listed